| Autor: |
Toyoda H; Pediatrics, Mie Univ., Ogawa C; Pediatric Oncology, National Cancer Center Hospital., Arakawa A; Pediatric Oncology, National Cancer Center Hospital., Yamanaka J; Pediatrics, National Center for Global Health and Medicine., Mochizuki S; Pediatrics, National Center for Global Health and Medicine., Saito AM; Clinical Research Center, NHO Nagoya Medical Center., Saito TI; Clinical Research Center, NHO Nagoya Medical Center., Goto H; Hematology and Oncology, Kanagawa Children's Medical Center., Horibe K; Clinical Research Center, NHO Nagoya Medical Center. |
| Jazyk: |
japonština |
| Zdroj: |
[Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2024; Vol. 65 (6), pp. 590-596. |
| DOI: |
10.11406/rinketsu.65.590 |
| Abstrakt: |
Many effective new agents for relapsed childhood acute lymphoblastic leukemia (ALL) are now becoming available, and international standard chemotherapy should be developed to optimize use of these agents. Randomized controlled trials (RCTs) are needed to establish a standard treatment, but few have been conducted for relapsed childhood ALL in Japan due to the small patient population. Participation in international RCTs is necessary to access sufficient patients for informative study results, but differences in approved drugs and healthcare systems between countries make this challenging. In 2014, the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) participated in an international study on standard-risk relapsed childhood ALL (IntReALL SR 2010) involving two RCTs and multiple drugs not approved in Japan, which was addressed by replacing the unapproved drugs with alternative approved drugs with the same or similar efficacy. This article discusses the historical background of treatment development for relapsed childhood ALL, our experience in participating in the IntReALL SR 2010 trial, and prospects for treating relapsed childhood ALL. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
